報價延遲最少15分鐘:2025/02/23 08:33 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.45 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-127.90/--
|
|
企業價值
7.23M
|
| 資產負債 |
|
每股賬面淨值
9.24
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
24.09M
|
|
每股收益
5.36
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/23 08:33 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment. |